Shanghai Shyndec Pharmaceutical Co Ltd

Shanghai Shyndec Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 3.59, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity FPT (free cash flow to total debt) is robust, supported by a free cash flow of 1.16 billion CNY and a low long-term debt of 93.44 million CNY, resulting in a debt-to-equity ratio of 0.01. The valuation snapshot shows a price-to-book ratio of 0.89, suggesting the company is trading at a discount to its book value. In terms of profitability, the company's return on equity (ROE) is 6.83%, and its return on assets (ROA) is 4.9%, both of which are below the industry median for pharmaceutical companies. The gross profit margin is 31.44%, and the operating margin is 14.02%, indicating a moderate level of profitability relative to its peers. The company's net income of 941.6 million CNY is supported by a revenue base of 9.36 billion CNY, but the net margin of 10.06% is in line with the industry average. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed in the available data. The lack of geographic diversification may expose the company to regulatory and economic risks specific to China. The company operates in a single business segment, which is typical for many pharmaceutical firms in the early stages of diversification. Looking ahead, the company's revenue is expected to grow, with a projected increase in the current fiscal year and the next fiscal year. The capital expenditure of -263.83 million CNY indicates a reduction in investment, which may signal a shift in strategic focus or a response to market conditions. The company's free cash flow of 1.16 billion CNY provides flexibility for future investments or shareholder returns. The risk assessment indicates a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. The company's valuation adjustments do not indicate any material overvaluation or undervaluation. Recent filings and transcripts do not highlight any major events or strategic shifts that would significantly impact the company's operations or financial performance. The company's financial health appears stable, with no immediate signs of distress or significant operational challenges.